司库奇尤单抗治疗附着点炎相关关节炎与幼年银屑病关节炎:一项随机、双盲、安慰剂对照、治疗撤药的3期试验
这项随机、双盲、安慰剂对照、治疗撤药的3期试验纳入2至<18岁、传统治疗应答不足的活动性ERA和JPsA患者,TP1开放标签司库奇尤单抗治疗至第12周,JIA ACR30应答者按1:1随机接受司库奇尤单抗或安慰剂至100周。结果显示司库奇尤单抗组疾病 flare 时间显著长于安慰剂组(27% vs 55%,HR 0.28,95%CI 0.13至0.63,p<0.001),安全性特征与成人银屑病关节炎和轴性脊柱关节炎适应症一致。
要点
- 司库奇尤单抗较安慰剂显著延长ERA和JPsA患者的疾病flare时间(27% vs 55%,HR 0.28,p<0.001)。
- 总体JIA人群中不良事件暴露调整发生率为290.7/100患者年(95%CI 230.2至362.3)。
- 严重不良事件暴露调整发生率为8.2/100患者年(95%CI 4.1至14.6)。
核心结论
- 司库奇尤单抗在ERA和JPsA患儿中较安慰剂显著延长至疾病flare的时间,安全性特征与成人银屑病关节炎和轴性脊柱关节炎适应症一致。
研究设计与样本
- 随机、双盲、安慰剂对照、治疗撤药的3期试验,纳入2至<18岁生物制剂初治的活动性ERA和JPsA患者。
- TP1开放标签皮下司库奇尤单抗(体重<50 kg者75 mg,≥50 kg者150 mg)治疗至第12周,第12周JIA ACR30应答者按1:1随机接受司库奇尤单抗或安慰剂至100周。
- TP2中flare的患者立即进入开放标签司库奇尤单抗TP3至第104周,主要终点为TP2至疾病flare的时间。
主要发现
- 共86例患者(中位年龄14岁)进入TP1开放标签司库奇尤单抗治疗。
- TP2中应答者(ERA 44/52;JPsA 31/34)接受司库奇尤单抗或安慰剂。
- 研究达到主要终点,ERA和JPsA患者中司库奇尤单抗组TP2至疾病flare的时间显著长于安慰剂组(27% vs 55%,HR 0.28;95%CI 0.13至0.63;p<0.001)。
- 总体JIA人群中不良事件暴露调整发生率为290.7/100患者年(95%CI 230.2至362.3)。
- 总体JIA人群中严重不良事件暴露调整发生率为8.2/100患者年(95%CI 4.1至14.6)。
关键数值与推荐
- 主要终点为TP2至疾病flare的时间,司库奇尤单抗组27% vs 安慰剂组55%(HR 0.28;95%CI 0.13至0.63;p<0.001)。
- 总体JIA人群不良事件暴露调整发生率为290.7/100患者年(95%CI 230.2至362.3)。
- 总体JIA人群严重不良事件暴露调整发生率为8.2/100患者年(95%CI 4.1至14.6)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment options in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) are currently limited. This trial aimed to demonstrate the efficacy and safety of secukinumab in patients with active ERA and JPsA with inadequate response to conventional therapy. METHODS: In this randomised, double-blind, placebo-controlled, treatment-withdrawal, phase 3 trial, biologic-naïve patients (aged 2 to <18 years) with active disease were treated with open-label subcutaneous secukinumab (75/150 mg in patients <50/≥50 kg) in treatment period (TP) 1 up to week 12, and juvenile idiopathic arthritis (JIA) American College of Rheumatology 30 responders at week 12 were randomised 1:1 to secukinumab or placebo up to 100 weeks. Patients who flared in TP2 immediately entered open-label secukinumab TP3 that lasted up to week 104. Primary endpoint was time to disease flare in TP2. RESULTS: A total of 86 patients (median age, 14 years) entered open-label secukinumab in TP1. In TP2, responders (ERA, 44/52; JPsA, 31/34) received secukinumab or placebo. The study met its primary end point and demonstrated a statistically significant longer time to disease flare in TP2 for ERA and JPsA with secukinumab versus placebo (27% vs 55%, HR, 0.28; 95% CI 0.13 to 0.63; p<0.001). Exposure-adjusted incidence rates (per 100 patient-years (PY), 95% CI) for total patients were 290.7/100 PY (230.2 to 362.3) for adverse events and 8.2/100 PY (4.1 to 14.6) for serious adverse events in the overall JIA population. CONCLUSIONS: Secukinumab demonstrated significantly longer time to disease flare than placebo in children with ERA and JPsA with a consistent safety profile with the adult indications of psoriatic arthritis and axial spondyloarthritis. TRIAL REGISTRATION NUMBER: NCT03031782.
引用
- Brunner HI, Foeldvari I, Alexeeva E, et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis. 2022. PMID: 35961761. doi:10.1136/ard-2022-222849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。